Physician profile
Michael E Leibowitz
NPI 1235119447
$1,702.25
in general payments reported to CMS, 2019-2025
19 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.70 · 2020: $104 · 2021: $306 · 2022: $440 · 2023: $273 · 2024: $271 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $306.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $244.92 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $209.27 | 2021-2024 | |
| Amgen INC. | $189.64 | 2021-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $167.47 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $149.06 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.43 | 2024 | |
| Pfizer INC. | $66.33 | 2021-2025 | |
| Abbott Laboratories | $60.58 | 2021-2023 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $44.66 | 2025 | Inspire |
| Baxter Healthcare | $43.52 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Atricure, INC. | $24.79 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System, Atricure Cryoice Cryosphere Cryoablation System |
| Boston Scientific Corporation | $24.65 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $24.04 | 2022 | |
| Astellas Pharma US INC | $18.20 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $17.65 | 2024 | Gemtesa |
| Evoke Pharma, INC. | $17.35 | 2021 | |
| Vistapharm, INC. | $14.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Leibowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.